NasdaqCM - Delayed Quote • USD
BioLineRx Ltd. (BLRX)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 5:51 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 1 | 1 |
Avg. Estimate | -0.29 | -0.29 | -1.03 | -0.93 |
Low Estimate | -0.29 | -0.29 | -1.03 | -0.93 |
High Estimate | -0.29 | -0.29 | -1.03 | -0.93 |
Year Ago EPS | -0.15 | -0.3 | -0.9 | -1.03 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 2 | 2 |
Avg. Estimate | 340k | 470k | 14.36M | 27.77M |
Low Estimate | 340k | 470k | 12.41M | 21.2M |
High Estimate | 340k | 470k | 16.32M | 34.34M |
Year Ago Sales | -- | -- | 4.8M | 14.36M |
Sales Growth (year/est) | -- | -- | 199.20% | 93.40% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.17 | -0.13 | -0.26 | -0.16 |
EPS Actual | -0.15 | -0.3 | -0.3 | -0.15 |
Difference | 0.02 | -0.17 | -0.04 | 0.01 |
Surprise % | 11.80% | -130.80% | -15.40% | 6.30% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.29 | -0.29 | -1.03 | -0.93 |
7 Days Ago | -0.29 | -0.29 | -1.03 | -0.93 |
30 Days Ago | -0.16 | -0.15 | -0.91 | -0.8 |
60 Days Ago | -0.16 | -0.15 | -0.01 | -0.05 |
90 Days Ago | -0.16 | -0.15 | -0.01 | -0.05 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | BLRX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -93.30% | -- | -- | 5.40% |
Next Qtr. | 3.30% | -- | -- | 10.90% |
Current Year | -14.40% | -- | -- | 4.50% |
Next Year | 9.70% | -- | -- | 13.10% |
Next 5 Years (per annum) | -25.00% | -- | -- | 10.94% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/17/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/26/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 11/20/2023 |
Maintains | HC Wainwright & Co.: Buy to Buy | 9/15/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/31/2023 |
Related Tickers
PLX Protalix BioTherapeutics, Inc.
1.1500
-2.54%
ENLV Enlivex Therapeutics Ltd.
1.4400
-0.69%
CANF Can-Fite BioPharma Ltd.
1.9800
+3.13%
EVGN Evogene Ltd.
0.6251
-4.91%
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
OCUP Ocuphire Pharma, Inc.
1.6100
+4.89%
ORMP Oramed Pharmaceuticals Inc.
2.4600
+6.96%
CGEN Compugen Ltd.
1.9200
+1.05%
CKPT Checkpoint Therapeutics, Inc.
1.4300
+0.70%
PLUR Pluri Inc.
5.36
+2.23%